Literature DB >> 28406709

Long-Term Outcomes in a Population-based Cohort with Respiratory Nontuberculous Mycobacteria Isolation.

Emily Henkle1,2, Shannon A Novosad1, Sean Shafer2, Katrina Hedberg2, Sarah A R Siegel1, Jennifer Ku1, Cara Varley1, D Rebecca Prevots3, Theodore K Marras4, Kevin L Winthrop1.   

Abstract

RATIONALE: The natural history of nontuberculous mycobacteria (NTM) respiratory infection in the general population is poorly understood.
OBJECTIVES: To describe the long-term clinical, microbiologic, and radiographic outcomes of patients with respiratory NTM isolates.
METHODS: We previously identified a population-based cohort of patients with respiratory NTM isolation during 2005-2006 and categorized patients as cases or noncases using the American Thoracic Society/Infectious Diseases Society of America pulmonary NTM disease criteria at that time. During 2014-2015, we reviewed medical charts of patients alive on January 1, 2007. Outcomes of interest were the proportion of baseline noncases who later met case criteria and the proportions of patients with culture conversion or findings consistent with persistent disease at least 2-5 years and at least 5 years after first isolation. We defined disease persistence radiographically as infiltrate, nodules, or cavities and microbiologically as a positive respiratory mycobacterial culture. We used logistic regression to evaluate factors associated with evidence of persistence.
RESULTS: The study included 172 patients (62% of 278 eligible); those not included either refused consent (n = 47) or were not located (n = 56). One hundred two (59%) included patients met case criteria at baseline. Mycobacterium avium complex was commonly isolated among baseline cases (n = 91 [89%]) and noncases (n = 52 [74%]). Overall, 57 (55%) baseline cases had died, as compared with 43 (61%) noncases (P = 0.47). Among baseline noncases, only four (5.7%) later met case criteria. Overall, 55 (54%) baseline cases and 6 (9%) noncases initiated NTM treatment. Among cases, cultures were converted in 25 (64.1%) treated versus 4 (40%) untreated patients (P = 0.04). Of 89 cases alive 2 years after isolation, 61 (69%) had additional radiography, and 35 (39%) had respiratory cultures. Of these individuals, 54 (89%) had radiographic evidence and 17 (49%) had microbiologic evidence of disease persistence. At 5 years after first isolation these figures were 36 (82%) and 13 (54%), respectively. Women were more likely to have persistent radiographic findings and microbiologic persistence, and patients with chronic obstructive pulmonary disease were less likely to have microbiologic persistence.
CONCLUSIONS: In the general population, follow-up beyond 2 years of patients with respiratory NTM isolation is limited. Among those with additional evaluations, at least half of individuals have persistent positive cultures or radiographic findings consistent with NTM at least 2 years after isolation.

Entities:  

Keywords:  Mycobacterium avium complex; natural history; nontuberculous mycobacteria; pulmonary disease

Mesh:

Year:  2017        PMID: 28406709      PMCID: PMC5566291          DOI: 10.1513/AnnalsATS.201610-801OC

Source DB:  PubMed          Journal:  Ann Am Thorac Soc        ISSN: 2325-6621


  14 in total

1.  Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems.

Authors:  D Rebecca Prevots; Pamela A Shaw; Daniel Strickland; Lisa A Jackson; Marsha A Raebel; Mary Ann Blosky; Ruben Montes de Oca; Yvonne R Shea; Amy E Seitz; Steven M Holland; Kenneth N Olivier
Journal:  Am J Respir Crit Care Med       Date:  2010-06-10       Impact factor: 21.405

Review 2.  An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases.

Authors:  David E Griffith; Timothy Aksamit; Barbara A Brown-Elliott; Antonino Catanzaro; Charles Daley; Fred Gordin; Steven M Holland; Robert Horsburgh; Gwen Huitt; Michael F Iademarco; Michael Iseman; Kenneth Olivier; Stephen Ruoss; C Fordham von Reyn; Richard J Wallace; Kevin Winthrop
Journal:  Am J Respir Crit Care Med       Date:  2007-02-15       Impact factor: 21.405

3.  Macrolide/Azalide therapy for nodular/bronchiectatic mycobacterium avium complex lung disease.

Authors:  Richard J Wallace; Barbara A Brown-Elliott; Steven McNulty; Julie V Philley; Jessica Killingley; Rebecca W Wilson; Deanna S York; Sara Shepherd; David E Griffith
Journal:  Chest       Date:  2014-08       Impact factor: 9.410

Review 4.  Slender, older women appear to be more susceptible to nontuberculous mycobacterial lung disease.

Authors:  Edward D Chan; Michael D Iseman
Journal:  Gend Med       Date:  2010-02

5.  Population-based Incidence of Pulmonary Nontuberculous Mycobacterial Disease in Oregon 2007 to 2012.

Authors:  Emily Henkle; Katrina Hedberg; Sean Schafer; Shannon Novosad; Kevin L Winthrop
Journal:  Ann Am Thorac Soc       Date:  2015-05

6.  Mortality after Respiratory Isolation of Nontuberculous Mycobacteria. A Comparison of Patients Who Did and Did Not Meet Disease Criteria.

Authors:  Shannon A Novosad; Emily Henkle; Sean Schafer; Katrina Hedberg; Jennifer Ku; Sarah A R Siegel; Dongseok Choi; Christopher G Slatore; Kevin L Winthrop
Journal:  Ann Am Thorac Soc       Date:  2017-07

7.  Quality of Life Questionnaire-Bronchiectasis: final psychometric analyses and determination of minimal important difference scores.

Authors:  Alexandra L Quittner; Anne E O'Donnell; Matthias A Salathe; Sandra A Lewis; Xiaoming Li; A Bruce Montgomery; Thomas G O'Riordan; Alan F Barker
Journal:  Thorax       Date:  2014-10-16       Impact factor: 9.139

8.  Treatment of Mycobacterium avium-intracellulare complex lung disease with a macrolide, ethambutol, and clofazimine.

Authors:  Stephen K Field; Robert L Cowie
Journal:  Chest       Date:  2003-10       Impact factor: 9.410

9.  Pulmonary mycobacterial infections due to Mycobacterium intracellulare-avium complex. Clinical features and course in 100 consecutive cases.

Authors:  D Y Rosenzweig
Journal:  Chest       Date:  1979-02       Impact factor: 9.410

10.  Pulmonary nontuberculous mycobacterial disease, Ontario, Canada, 1998-2010.

Authors:  Theodore K Marras; David Mendelson; Alex Marchand-Austin; Kevin May; Frances B Jamieson
Journal:  Emerg Infect Dis       Date:  2013-11       Impact factor: 6.883

View more
  6 in total

1.  Mortality after Respiratory Isolation of Nontuberculous Mycobacteria. A Comparison of Patients Who Did and Did Not Meet Disease Criteria.

Authors:  Shannon A Novosad; Emily Henkle; Sean Schafer; Katrina Hedberg; Jennifer Ku; Sarah A R Siegel; Dongseok Choi; Christopher G Slatore; Kevin L Winthrop
Journal:  Ann Am Thorac Soc       Date:  2017-07

2.  Prescribing Patterns for Treatment of Mycobacterium avium Complex and M. xenopi Pulmonary Disease in Ontario, Canada, 2001-2013.

Authors:  Sarah K Brode; Hannah Chung; Michael A Campitelli; Jeffrey C Kwong; Alex Marchand-Austin; Kevin L Winthrop; Frances B Jamieson; Theodore K Marras
Journal:  Emerg Infect Dis       Date:  2019-07       Impact factor: 6.883

3.  High mortality in patients with Mycobacterium avium complex lung disease: a systematic review.

Authors:  Roland Diel; Marc Lipman; Wouter Hoefsloot
Journal:  BMC Infect Dis       Date:  2018-05-03       Impact factor: 3.090

4.  Optimization and Lead Selection of Benzothiazole Amide Analogs Toward a Novel Antimycobacterial Agent.

Authors:  Mary A De Groote; Thale C Jarvis; Christina Wong; James Graham; Teresa Hoang; Casey L Young; Wendy Ribble; Joshua Day; Wei Li; Mary Jackson; Mercedes Gonzalez-Juarrero; Xicheng Sun; Urs A Ochsner
Journal:  Front Microbiol       Date:  2018-09-20       Impact factor: 5.640

5.  Time-to-positivity of Mycobacterium avium complex in broth culture associates with culture conversion.

Authors:  Christina M Mingora; Bryan A Garcia; Kevin C Mange; Dayton W Yuen; Monika Ciesielska; Jakko van Ingen; Patrick A Flume; Susan E Dorman
Journal:  BMC Infect Dis       Date:  2022-03-12       Impact factor: 3.090

6.  Nontuberculous mycobacterial infection in a tertiary care center in Mexico, 2001-2017.

Authors:  Bruno Ali Lopez-Luis; José Sifuentes-Osornio; María Teresa Pérez-Gutiérrez; Bárbara Chávez-Mazari; Miriam Bobadilla-Del-Valle; Alfredo Ponce-de-León
Journal:  Braz J Infect Dis       Date:  2020-05-16       Impact factor: 3.257

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.